Skip to main content
Log in

Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis

  • Short Communications
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

The pharmacokinetics of ganciclovir was evaluated in a 73-year old anuric, haemodialyzed patient given 1.25 mg·kg-1 at the end of each haemodialysis session, three times per week.

A biexponential decrease in plasma ganciclovir was observed, with a peak concentration of 3.7 mg·1-1 followed by a steady state value of 2.6 mg·1-1 for almost 40 h. The total plasma clearance was 0.05 ml·min-1·kg-1, the volume of distribution at steady state was 0.61·kg-1, the elimination half life was 132 h, the area under curve was 372 μg·h·ml-1, the mean residence time was 190 h, and the percentage of ganciclovir cleared from plasma after a 5 h haemodialysis session was 52.1%.

The simulated pharmacokinetics over one month, following the same scheme of administration, did not suggest marked accumulation of ganciclovir. These results were obtained after a reduction of 58% in the recommended dose in patients with impaired renal function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Boulieu R, Bleyzac N, Ferry S (1991) High performance liquid chromatographic determination of ganciclovir in plasma. J Chromatogr Biomed Applic 567: 480–484

    Google Scholar 

  2. Davis CL, Springmeyer S, Gmerek BJ (1990) Central nervous system side effects of ganciclovir. N Engl J Med 322: 933–934

    Google Scholar 

  3. Fletcher C, Sawchuk R, Chinnock B, Miranda P de (1986) Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 40: 281–286

    Google Scholar 

  4. Lake KD, Fletcher CV, Love KR, Brown DC, Joyce LD, Pritzker MR (1988) Ganciclovir pharmacokinetics during renal impairment. Antimicrob Agents Chemother 32: 1899–1900

    Google Scholar 

  5. Rondeau E, Farquet C, Fries D, Sraer JD (1990) Pharmacocinétique du ganciclovir (Cymévan®) chez les transplantés rénaux. Lettre L'infectiologue, February, pp 22–25

  6. Sommadossi JP, Bevan R, Ling T, Lee F, Mastre B, Chaplin MD, Nerenberg C, Koretz S, Buhles WC (1988) Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis 3 [Suppl 10]: 507–514

    Google Scholar 

  7. Swan SK, Munar MY, Wigger MA, Bennett WM (1991) Pharmacokinetics of ganciclovir in a patient undergoing haemodialysis. Am J Kidney Dis 17: 69–72

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Combarnous, F., Fouque, D., Bernard, N. et al. Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis. Eur J Clin Pharmacol 46, 379–381 (1994). https://doi.org/10.1007/BF00194410

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00194410

Key words

Navigation